This Month in Myeloma

If you have questions I believe you’ll find it right here on Project 611. If you need more information I’ll get it for you, just leave a comment below and I’ll get right back to you.
I’ll see you on Saturday at 2pm EST for Saturday at the oldies with me, Uncle Niel your Psychedelic Relic and The Traveling Band of Merry Misfits.

NOW This Month in Myeloma - January 2015

MMRF News: The MMRF announces a promising collaboration with GNS Healthcare
In the Pipeline: Learn about current clinical trials
Research Update: Get the latest developments
MMRF Events Feature: Get your tickets for Laugh for Life: New York

The Latest News
Multiple Myeloma Patient Survey
We want to hear about your journey with myeloma- so we have commissioned a survey for patients so we can learn more from you. We hope you consider participating! Please note, this is a survey for patients living in the U.S. only. If you are interested, please click the following link to learn more.

The MMRF announces a promising collaboration with GNS Healthcare
GNS Healthcare and the MMRF bring powerful analytics to genomic and clinical data to identify potential new multiple myeloma therapies.

Highlights from the 2014 ASH Annual Meeting Teleconference
Listen to highlights from the MMRF 2014 ASH Annual Meeting Teleconference. Hear about many promising therapeutic options in clinical trials for myeloma patients including elotuzamab, ixazomib, SAR650984, and ibrutinib.


ASH CME Education

  • Physicians & Nurses: Gain insights into the latest clinical data and updates in multiple myeloma from leading experts Drs. Suzanne Lensch and Joel Mikhael. Earn your CME and CE credits now!
  • Physicians & Nurses: Personalizing Multiple Myeloma Treatment for Maximum Benefit. Question and answer based, CME-certified Qstream course.
In the Pipeline
More Exciting New Trials
Just before the end of December, we opened four new clinical trials, making 2014 a record breaking year. This is exciting and essential because without trials, new treatments remain stuck in laboratories and can’t come to market. We and our partners have great hope for these new possibilities.

  • A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
  • A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
  • An Open-Label, Single Arm, Phase II Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma
  • Phase 2 Randomized trial of continuation of post-transplant maintenance with single-agent lenalidomide vs. consolidation/maintenance with ixazomib-lenalidomide-dexamethasone in patients with residual myeloma
Clinical Trials
If you are a newly diagnosed or relapsed/refractory patient, there may be a clinical trial that is right for you.

Research Updates
Learn about the latest developments in the fast moving field of myeloma research.

MMRF Events
Laugh for Life: New York—May 5, 2015, Pier Sixty, New York, NY
This premier comedy event celebrates life through laughter and has raised over $5 million for the MMRF’s cancer research since 2003. It includes a silent and live auction, cocktail reception, dinner and a hilarious comedy show. Past celebrity headliners include Susie Essman, Robert Klein, Jim Gaffigan, Tom Papa and John Pinette. This year’s lineup is sure to be equally entertaining. Don’t miss it!


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s